No Data
Guosen: Continuously recommending Innovative Drugs and paying attention to investment opportunities in Medical Devices.
Currently, the Industry is undergoing significant supply-side structural reforms, and the collective procurement of Pharmaceuticals and Medical Devices is also nearing completion, with the expectation of entering a new growth cycle in 2025.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
BOCOM INTL: The medical insurance work conference again mentioned the Class B catalog and support for the development of commercial insurance, focusing on opportunities related to policy easing.
Recently, the pharmaceutical Sector has experienced a significant fluctuation followed by a decline. Considering that the Sector's valuation is still at a historical low, coupled with the upcoming bullish policies related to finance and medical insurance/commercial insurance and improved liquidity, this institution believes there is still room for further recovery.
[Brokerage Focus] BOCOM INTL expects commercial insurance to further develop by 2025, assisting in resolving payment issues for Innovative Drugs.
Jinwu Finance | BOCOM INTL expects that by 2025, commercial insurance will likely develop further, helping to solve payment issues for Innovative Drugs. At the same time, an innovative payment mechanism differentiated between Category B catalog and commercial insurance may alleviate the difficulties faced by Innovative Drug and device companies in entering hospitals and obtaining reimbursement. Recently, the pharmaceutical Sector has seen a significant decline after substantial fluctuations. Considering that the sector's valuation remains at historical lows, coupled with the introduction of favorable policies related to finance and medical insurance/commercial insurance, as well as improved liquidity, the bank believes there is still potential for further recovery. The bank continues to recommend potential beneficiary symbols of subsequent policy space, including: 1) AKESO (09926), Legend Health.
UBS Group: Reiterates AKESO (09926) 'Buy' rating with the Target Price raised to HKD 88.1.
UBS Group believes that the inclusion of AK112 and AK104 in the National Medical Insurance Pharmaceutical Directory (NRDL) in 2024 will drive the company's product sales growth next year.
BOCOM INTL: Assigns a "Leading" rating to the domestic Pharmaceutical Industry. Shanghai establishes a 10 billion yuan M&A Fund, which is beneficial for accelerating industry consolidation.
BOCOM INTL believes that the pharmaceutical Sector still has further room for recovery.
MayFlower : It was predictable..
Midnite52 : yep